White House lays out sprawl­ing new plan to shore up phar­ma and API man­u­fac­tur­ing

As the US in­creas­ing­ly re­lies on for­eign drug and ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) man­u­fac­tur­ing, par­tic­u­lar­ly from Chi­na and In­dia, the Biden-Har­ris ad­min­is­tra­tion ear­ly Tues­day morn­ing re­leased a new re­port spelling out how the US needs to bet­ter tack­le the three pil­lars of a ro­bust and re­silient sup­ply chain by boost­ing qual­i­ty, lo­ca­tion di­ver­si­ty, and re­dun­dan­cy.

Where­as the pan­dem­ic laid bare how much the US re­lies on es­sen­tial im­ports, the pre­vi­ous ad­min­is­tra­tion fo­cused its sup­ply chain ef­forts on adding new do­mes­tic man­u­fac­tur­ing, with in­vest­ments in up­start Phlow, and a ques­tion­able $765 mil­lion loan through the ad­min­is­tra­tion’s de­vel­op­ment fi­nance arm to cam­era mak­er Ko­dak.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER